Literature DB >> 16574669

Francisella tularensis LPS induces the production of cytokines in human monocytes and signals via Toll-like receptor 4 with much lower potency than E. coli LPS.

Ana I Dueñas1, Mónica Aceves, Antonio Orduña, Ramón Díaz, Mariano Sánchez Crespo, Carmen García-Rodríguez.   

Abstract

Francisella tularensis is a virulent Gram-negative intracellular pathogen. To address the signaling routes involved in the response of host cells to LPS from F. tularensis live vaccine strain (LVS), experiments were performed in transiently transfected 293 cells. Induction of kappaB-driven transcriptional activity by 2.5 mug ml(-1) F. tularensis LPS isolated by phenol-water and ether-water extraction, was observed in cells transfected with Toll-like receptor (TLR) 4 and MD-2, although CD14 was required for optimal induction. Conversely, TLR2, TLR2/TLR1 or TLR2/TLR6 transfected cells did not show kappaB-driven transcriptional activity in the presence of F. tularensis LPS. In human monocytic cells, F. tularensis LPS activated extracellular signal-regulated kinases and the production of pro-inflammatory proteins. Concentrations of 5-10 mug ml(-1) F. tularensis LPS elicited a similar pattern of mRNA and protein induction than 0.1 mug ml(-1) E. coli LPS, including the expression of CXC chemokines (IL-8, Gro and IFN-gamma-inducible protein-10); CC chemokines (monocyte chemoattractant protein-1 and -2, macrophage-derived chemoattractant, macrophage inflammatory protein-1alpha and -1beta and RANTES (regulated upon activation, normal T cell expressed and secreted) and pro-inflammatory cytokines (IL-6 and tumor necrosis factor alpha). Altogether, these data indicate that LPS from F. tularensis LVS signals via TLR4 at higher concentrations than those required for E. coli LPS, which may explain the inflammatory reaction and the low endotoxic response associated to vaccination with LVS in humans.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16574669     DOI: 10.1093/intimm/dxl015

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  38 in total

1.  Proteomic analysis of bronchoalveolar lavage fluid proteins from mice infected with Francisella tularensis ssp. novicida.

Authors:  Susan M Varnum; Bobbie-Jo M Webb-Robertson; Joel G Pounds; Ronald J Moore; Richard D Smith; Charles W Frevert; Shawn J Skerrett; David Wunschel
Journal:  J Proteome Res       Date:  2012-06-22       Impact factor: 4.466

2.  Monophosphoryl Lipid A Enhances Efficacy of a Francisella tularensis LVS-Catanionic Nanoparticle Subunit Vaccine against F. tularensis Schu S4 Challenge by Augmenting both Humoral and Cellular Immunity.

Authors:  Katharina Richard; Barbara J Mann; Aiping Qin; Eileen M Barry; Robert K Ernst; Stefanie N Vogel
Journal:  Clin Vaccine Immunol       Date:  2017-03-06

3.  In vivo mechanisms involved in enhanced protection utilizing an Fc receptor-targeted mucosal vaccine platform in a bacterial vaccine and challenge model.

Authors:  Constantine Bitsaktsis; Zulfia Babadjanova; Edmund J Gosselin
Journal:  Infect Immun       Date:  2014-10-13       Impact factor: 3.441

4.  A comprehensive transposon mutant library of Francisella novicida, a bioweapon surrogate.

Authors:  Larry A Gallagher; Elizabeth Ramage; Michael A Jacobs; Rajinder Kaul; Mitchell Brittnacher; Colin Manoil
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-10       Impact factor: 11.205

5.  Novel catanionic surfactant vesicle vaccines protect against Francisella tularensis LVS and confer significant partial protection against F. tularensis Schu S4 strain.

Authors:  Katharina Richard; Barbara J Mann; Lenea Stocker; Eileen M Barry; Aiping Qin; Leah E Cole; Matthew T Hurley; Robert K Ernst; Suzanne M Michalek; Daniel C Stein; Philip Deshong; Stefanie N Vogel
Journal:  Clin Vaccine Immunol       Date:  2013-12-18

6.  Francisella tularensis infection-derived monoclonal antibodies provide detection, protection, and therapy.

Authors:  Anne G Savitt; Patricio Mena-Taboada; Gloria Monsalve; Jorge L Benach
Journal:  Clin Vaccine Immunol       Date:  2009-01-28

Review 7.  Tularemia vaccines.

Authors:  Daniela Putzova; Iva Senitkova; Jiri Stulik
Journal:  Folia Microbiol (Praha)       Date:  2016-05-19       Impact factor: 2.099

8.  Differing effects of interleukin-10 on cutaneous and pulmonary Francisella tularensis live vaccine strain infection.

Authors:  Dennis W Metzger; Sharon L Salmon; Girish Kirimanjeswara
Journal:  Infect Immun       Date:  2013-03-25       Impact factor: 3.441

Review 9.  Vaccines against tularemia.

Authors:  Eileen M Barry; Leah E Cole; Araceli E Santiago
Journal:  Hum Vaccin       Date:  2009-12-11

10.  Differentiation of gram-negative bacterial aerosol exposure using detected markers in bronchial-alveolar lavage fluid.

Authors:  David Wunschel; Bobbie-Jo Webb-Robertson; Charles W Frevert; Shawn Skerrett; Nat Beagley; Alan Willse; Heather Colburn; Kathryn Antolick
Journal:  PLoS One       Date:  2009-09-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.